Galenika Announces the Distribution of Aesthetic Medicine Products
Galenika Expands Its Dermaceutical Portfolio with New Global Partner
Pharmaceutical company Galenika continues to strategically expand its portfolio, this time through a partnership with the Austrian company Croma-Pharma, a global player present in markets worldwide and one of Europe’s leading manufacturers of premium hyaluronic acid-based products, a key ingredient in skincare.
With this partnership, Galenika is launching the distribution of seven new products in the field of aesthetic medicine for the markets of Serbia and Bosnia and Herzegovina. Croma-Pharma operates in 80 markets globally and adheres to the highest quality standards, which is a key requirement for this partnership.
The new five-year cooperation agreement with Croma-Pharma further strengthens Galenika’s market position and enables the continued expansion of its portfolio of modern and effective pharmaceutical products of the highest quality.
“With this partnership, Galenika continues to expand its product portfolio in a segment that is becoming increasingly important today. Entering the field of aesthetic medicine is a significant step for the company, and at the same time, we continue to expand our dermaceutical portfolio, which is already present in the market. We are pleased to have found a global partner that shares Galenika’s commitment to health and the highest quality products,” said Rikardo Vian Markes, CEO of Galenika.
Croma-Pharma is a leader in the field of products for minimally invasive aesthetic procedures and has its products in 80 markets worldwide, including Europe, the United States, Canada, China, Australia, and New Zealand. The company offers a comprehensive and innovative portfolio in the aesthetic medicine segment. In addition to aesthetic medicine, Croma-Pharma also produces hyaluronic acid-based medical devices for use in orthopedics and ophthalmology, which are gaining increasing importance in medicine. Moreover, the company invests heavily in research and development of new products. By applying its innovative crosslinking technology (MACRO Core Technology), Croma-Pharma ensures the production of products with predefined high-quality characteristics.
“Aesthetic medicine has become much more than it once was. At Croma-Pharma, we are driven by the ambition to constantly find value for our partners. Quality, reliability, and a scientific approach have positioned us well in both domestic and global markets. We recognize that Galenika shares our values, and because of this, we believe they are the right partner for a long-term collaboration in achieving our shared global goals,” said Andreas Prinz, CEO of Croma-Pharma.
